# Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT03552471** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Folate Receptor Alpha Positive
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Recurrent Uterine Serous Carcinoma
- Recurrent Uterine Carcinosarcoma
- Platinum Resistant Ovarian Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Mirvetuximab Soravtansine
- **OTHER:** Pharmacokinetic Study
- **DRUG:** Rucaparib Camsylate

## Key facts

- **NCT ID:** NCT03552471
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-12
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-12-19
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552471, "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03552471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*